secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088340
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports Q2 2024 net loss of $36.1M; cash $278.4M, runway into 2026
---------------------------------------------------------------------------

- Cash, equivalents and marketable securities totaled $278.4M; expected runway into 2026.
- Net loss of $36.1M for Q2 2024; R&D expense $29.1M, G&A $7.0M.
- Phase 3 RINGSIDE Part B (AL102) for desmoid tumors fully enrolled; topline data expected H2 2025.
- IND submissions for IM-1021 and IM-3050 anticipated in Q1 2025.
- Business development transactions with Atreca, Nectin Therapeutics, Bluefin, OncoResponse expanding ADC toolbox.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924088340/0001104659-24-088340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924088340/tm2421310d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer